Finance

Lists
4527:TYO
Rohto Pharmaceutical Co Ltd
¥2,631.50
-1.13%
(-30.00) 1D
Nov 20, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4527...
Open
¥2,624
High
¥2,702
Low
¥2,620
Mkt. cap
621.50B
Avg. vol.
1.32M
Volume
1.72M
Dividend
1.90%
Quarterly dividend
¥12
Ex-dividend date
Sep 29, 2026
P/E ratio
18.70
52-wk high
¥3,122
52-wk low
¥2,218
EPS
¥141
Shares outstanding
113.97M
No. of employees
9K
Open
¥2,624
High
¥2,702
Low
¥2,620
Mkt. cap
621.50B
Avg. vol.
1.32M
Volume
1.72M
Dividend
1.90%
Quarterly dividend
¥12
Ex-dividend date
Sep 29, 2026
P/E ratio
18.70
52-wk high
¥3,122
52-wk low
¥2,218
EPS
¥141
Shares outstanding
113.97M
No. of employees
9K
News stories
From web sources and news partners
Profile
Rohto Pharmaceutical Co., Ltd. is a Japanese multinational corporation specializing in fast-moving consumer goods and pharmaceuticals, headquartered in Ikuno-ku, Osaka, Japan. The company primary focuses on skin and eye care products. They also produce cosmetics, supplements, and over-the-counter medications. Wikipedia
About Rohto Pharmaceutical Co Ltd
CEOKunio Yamada | Kunio Yamada
Employees9.29K
Founded1899
HeadquartersOsaka, Osaka, Japan
SectorConsumer Staples
IndustryPersonal care products
Last report
Nov 12, 2026
Fiscal period
Q2 2027
- / -
Revenue / Est. (JPY)
87.38B / 89.18B
-2.01%miss
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
88.81B
90.65B
91.62B
87.38B
Cost of goods sold
37.68B
40.28B
40.03B
39.41B
Cost of revenue
37.68B
40.28B
40.03B
39.41B
Research and development expenses
-
13.73B
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
36.88B
19.39B
37.93B
40.68B
Operating expense
37.03B
42.90B
38.02B
40.73B
Total operating expenses
74.71B
83.18B
78.05B
80.14B
Operating income
14.10B
7.47B
13.57B
7.24B
Other non operating income
116.00M
445.00M
195.00M
249.00M
EBT including unusual items
15.22B
8.06B
14.80B
8.50B
EBT excluding unusual items
15.24B
8.12B
14.49B
7.36B
Income tax expense
4.65B
1.98B
3.75B
2.91B
Effective tax rate
30.55%
24.58%
25.36%
34.27%
Other operating expenses
-
-
-
-
Net income
10.63B
5.97B
10.65B
5.85B
Net profit margin
11.97%
6.58%
11.62%
6.69%
Earnings per share
-
-
-
-
Interest and investment income
573.00M
759.00M
1.15B
362.00M
Interest expense
-311.00M
-371.00M
-320.00M
-300.00M
Net interest expenses
262.00M
388.00M
833.00M
62.00M
Depreciation and amortization charges
-
7.69B
-
-
EBITDA
17.39B
11.82B
17.92B
11.80B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps